Transcatheter tricuspid valve repair and replacement
Ask the expert
The report presents a summary of reimbursement situation for minimally invasive tricuspid valve repair and replacement procedures. The procedures performed via endovascular and transapical approach are considered.
Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations).
Reimbursement analysis will cover the following procedures:
- transcatheter tricuspid valve repair;
- transcatheter tricuspid valve replacement.
The diagnosis of nonrheumatic tricuspid (valve) insufficiency is considered as an indication for procedures.
The only reimbursement within public / statutory health insurance systems is considered.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
Table of content is not available at the moment. Report is still ongoing.
In April 2022, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects which received a subsidy under the "Subsidy scheme for promising care" in 2022 for research of a transcatheter tricuspid valve repair in severe leakage of the tricuspid valve and precision radiation in epilepsy. In total, five projects will receive a subsidy in 2022.Read more
In November 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (percutaneous implantation of pulmonary artery pressure sensors in chronic heart failure and coronary sinus narrowing device implantation for refractory angina), one new Medical Technologies Guidance (Synergo for non-muscle-invasive bladder cancer), one new Diagnostic Guidance (SeHCAT for diagnosing bile acid diarrhea), and four new Medtech Innovation Briefings (clonoSEQ for minimal residual disease, CerebAir for continuous EEG monitoring, 24/7 EEG SubQ for epilepsy, Paige Prostate for prostate cancer). Also, three new clinical guidelines were published, and six were updated.Read more